Douglas E. Williams, PhD, is the Chairman of the Board of CAMP4 Therapeutics. Dr. Williams is a veteran of the biopharma industry with more than 30 years of experience in research and development and contributions to the development of several innovative drug products.

Dr. Williams most recently served as President of R&D at Sana Biotechnology. He previously served as the Founding President and Chief Executive Officer of Codiak BioSciences, and as Executive Vice President, Research and Development at Biogen from. Prior to Biogen, Dr. Williams served as Chief Executive Officer of ZymoGenetics, which was acquired by Bristol Myers Squibb during his tenure. Earlier in his career, Dr. Williams held a variety of leadership positions in biotech, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, Senior Vice President and Washington Site Leader at Amgen, and Executive Vice President, Chief Technology Officer, and member of the Board of Directors at Immunex. He has served on the Boards of Directors and Advisory Boards of more than two dozen biotechnology companies and is currently Chairman of the Boards of CAMP4 Therapeutics, Draig Therapeutics and Climb Bio, and a member of the Boards of eGenesis, Ormoni, and Mosaica Medicines.

Dr. Williams earned his PhD from The State University at Buffalo Roswell Park Division and completed his postdoctoral studies at Indiana University School of Medicine.

Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics.

Mr. Mandel-Brehm was previously an entrepreneur partner with Polaris Partners and held key business development and operations leadership roles at leading biotech companies. He served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions. Prior to Biogen, Mr. Mandel-Brehm was at Genzyme as part of the business development group for the company’s rare disease business unit. He is currently a Board Director at Vico Therapeutics, a company he co-founded, and ProMIS Neuroscience.

Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Steve Holtzman is Executive Chair of the Board of Directors of Qihan Biotech and Executive Chair of the Board of Directors of Manifold Bio. He is also a member of the Board of Directors of CAMP4 Therapeutics, and Molecular Partners, as well as a strategic advisor to Digital Bio, Amplify Bio, and Babylon Biosciences.

Mr. Holtzman previously served as the founding Chief Executive Officer and member of the Board of Directors of Decibel Therapeutics, Executive Vice President of Corporate Development at Biogen, co-founder, Chief Executive Officer, and Chair of the Board of Directors of Infinity Pharmaceuticals, Chief Business Officer of Millennium Pharmaceuticals, and co-founder, Executive Vice President, and member of the Board of Directors of DNX Corporation. Mr. Holtzman is a member of the Board of Trustees of the Berklee College of Music and a senior fellow at the Belfer Center for Science and International Affairs at the Harvard Kennedy School. He was appointed by President Clinton to the National Bioethics Advisory Commission and served as a member and vice chair of the Board of Trustees of the Hastings Center for Ethics and the Life Sciences.

Mr. Holtzman earned his undergraduate degree in philosophy from Michigan State University and his graduate degree in philosophy from Oxford University, which he attended as a Rhodes Scholar.

Michael F. MacLean is a senior executive with more than 35 years of financial leadership experience in the biotechnology and life sciences industries, with extensive expertise in public company reporting, capital markets transactions, internal controls, and corporate governance.

Mr. MacLean most recently served as Chief Financial Officer of Avidity Biosciences, joining prior to the company’s initial public offering and leading its finance and business functions through its IPO and subsequent growth as a multinational organization. Previously, he served as Chief Financial Officer of Akcea Therapeutics and as Chief Financial Officer of PureTech Health. Earlier in his career, Mr. MacLean held senior finance roles at Biogen, including Senior Vice President, Finance and Chief Accounting Officer, and served as an audit partner at a Big Four accounting firm. He also served on the Board of Directors of Verve Therapeutics and as Chair of its Audit Committee.

Mr. MacLean earned a BS in Accounting from Boston College.

Amir Nashat, ScD, is the CEO of Soufflé Therapeutics and an Entrepreneur Partner at Polaris Partners, where he previously served as Managing Partner. While at Polaris, he worked with groundbreaking companies such as Alnylam Pharmaceuticals and Acceleron Pharma, and led investments in/founded: Dewpoint Therapeutics, Fate Therapeutics, Jnana Pharmaceuticals, Living Proof, Morphic Therapeutics, Paratus Sciences, Receptos Pharmaceuticals, and Scholar Rock. Mr. Nashat currently serves as a director of CAMP4 Therapeutics, Dewpoint, Matter Neuroscience and Paratus.

He serves on the investment committee of Partners Innovation Fund and is a member of the Innovation Advisory Board of Mass General Brigham. Amir helped to launch the MIT Sandbox Innovation Fund as its President.

Mr. Nashat completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology, with a minor in Biology, and his MS and BS in Materials Science and Mechanical Engineering from the University of California, Berkeley.

Andy Schwab is a Founder and Managing Partner of 5AM Ventures.

Prior to founding 5AM, Mr. Schwab was a Principal at Bay City Capital where he was involved with companies such as Cubist, PTC Therapeutics, and Syrrx. Previously, he served as Vice President of Business Development at Digital Gene Technologies and as a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of CAMP4 Therapeutics, DVS (acquired by Fluidigm), Enliven, Escient Pharmaceuticals (Incyte), Flexion Therapeutics (Pacira), Ikaria (Mallinckrodt), Ilypsa (Amgen), Precision NanoSystems (Danaher), Radionetics, RareCyte, Scientist.com (GHO Capital), Skye Bioscience, and TMRW. Mr. Schwab has also served on the Boards of Trustees of the California Academy of Sciences, Davidson College, and the National Venture Capital Association.

Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of its 1992 Final Four soccer team.

Murray Stewart, DM, FRCP, is a Senior Medical Advisor to several biopharmaceutical companies.

Dr. Stewart previously served as Chief Medical Officer at GlaxoSmithKline and subsequently as Chief Medical Officer and Head of Research and Development at Rhythm Pharmaceuticals and Novelion Therapeutics. Prior to joining the pharmaceutical industry, Dr. Stewart worked as a diabetes consultant and senior lecturer and served as Consultant Physician, Honorary Senior Lecturer, and Head of Clinical Services at the Diabetes Centre, Newcastle upon Tyne, in the UK, where his research focused on lipid metabolism in type-2 diabetes. He currently serves as a board director of X4 Pharmaceuticals.

Dr. Stewart completed his medical training at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.

Richard Young, PhD, is a Member of the Whitehead Institute for Biomedical Research and Professor of Biology at the Massachusetts Institute of Technology.

Dr. Young has served as an advisor to the National Institutes of Health, the World Health Organization, the Vatican, and numerous scientific societies and journals, and has founded and advised numerous companies in the biotechnology and pharmaceutical industry. His honors include membership in the National Academy of Sciences, the Chiron Corporation Biotechnology Research Award, Yale’s Wilbur Cross Medal, and recognition by Scientific American as one of the top 50 leaders in science, technology, and business (2006).

Dr. Young’s research focuses on gene regulatory circuitry in health and disease, with accomplishments ranging from the development of genome-wide analysis technologies to the discovery of the core regulatory circuitry of human embryonic stem cells. He joined Whitehead Institute and MIT in 1984 following postdoctoral research at Stanford University.

Dr. Young received his PhD in Molecular Biophysics and Biochemistry from Yale University and conducted his postdoctoral research at Stanford University.

Dr. Karen Adelman is the Edward S. Harkness Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a member of the Gene Regulation Observatory at the Broad Institute.

Dr. Adelman also serves as the Associate Director for Basic Science at the Harvard Cancer Center and is a member of the Ludwig Center at Harvard Medical School. She established her lab at the National Institute of Environmental Health Sciences (NIEHS, NIH) and was promoted to Senior Investigator. Later, Dr. Adelman was recruited to Harvard Medical School. She is engaged in the Biological and Biomedical Sciences graduate program, teaching in the first-year molecular biology course and serving as Director of Admissions. Dr. Adelman received the NIH Early Career Award and the NIH Directors award for Scientific Achievement. She sits on the Scientific Advisory Boards for Keystone Symposia, Max Planck Institutes and the Mendel Lecture series, and has been elected to the American Academy of Arts and Sciences and European Molecular Biology Organization.

Dr. Adelman earned her PhD from the Université de Paris VI, Sorbonne, working at the Institut Pasteur on gene regulation. She carried out her postdoctoral research with Dr. John Lis at Cornell University.

David Bumcrot, PhD, is Scientific Fellow and former Chief Scientific Officer of CAMP4.

Dr. Bumcrot previously led groups at innovative biotech companies advancing novel technologies toward clinical development. He was one of the first employees at Alnylam Pharmaceuticals, where he spent ten years working to make RNA interference-based drugs a reality for multiple indications, including key contributions to a first-in-class systemically administered siRNA therapeutic tested in an oncology clinical trial. He subsequently joined Editas Medicine, where his team established the company’s initial therapeutic programs utilizing CRISPR technology.

Dr. Bumcrot received his BS from Cornell University and his PhD in molecular biology from the University of Pennsylvania. He completed a postdoctoral fellowship at Harvard University.

Dr. Chung is a clinical and molecular geneticist. She directs NIH-funded research in human genetics of autism, pulmonary hypertension, breast cancer, obesity, diabetes, and birth defects including congenital diaphragmatic hernia and congenital heart disease. She is a national leader in the ethical, legal, and social implications of genomics.

Dr. Chung has identified the genetic basis of more than 60 rare diseases. She leads the GUARDIAN study to expand newborn screenings for genetic disorders and advance development of personalized therapies for children with these conditions. Dr. Chung also leads national collaborations to identify the origins of autism and guide impactful therapies and services. Her goal is to enhance understanding of autism contributors, discover how the condition changes over lifespans and identify how to support individuals.

Dr. Chung has received the National Organization of Rare Disorders Rare Impact Award and is a member of the National Academy of Medicine and the American Academy of Physicians. She earned her BA in biochemistry from Cornell University, MD from Cornell University Medical College and PhD in genetics from The Rockefeller University. 

Rachel Meyers, PhD, is a Scientific Fellow at CAMP4 Therapeutics.

Dr. Meyers is an entrepreneurial scientist with more than 25 years of drug discovery and development expertise and extensive experience building research and development organizations. She previously served as Founder and Chief Scientific Officer at Faze Medicines, served as Senior Vice President of Research and RNAi Lead Development at Alnylam Pharmaceuticals. Prior to Alnylam, Dr. Meyers was a senior scientist at Millennium Pharmaceuticals. She currently serves as a member of the Board of Directors of Korro Bio and Atlas NewCo and as a scientific advisor to CAMP4 Therapeutics and Alnylam Pharmaceuticals and Arrakis Therapeutics as a founding partner of Sunrise Bioventures, and as acting Chief Executive Officer of AmyGo Solutions. Dr. Meyers also serves as a mentor with several local and national biotech entrepreneurial programs and previously served on the National Advisory Council on Innovation and Entrepreneurship during the Biden administration.

Dr. Meyers completed her postdoctoral training with Lew Cantley at Harvard Medical School in the field of signal transduction and received her PhD from Nobel laureate Phil Sharp at MIT in the field of in vitro transcription.

Dr. Benjamin Neale is a core institute member at the Broad Institute of MIT and Harvard, where he is co-director of the Stanley Center for Psychiatric Research and serves on the institute’s Executive Leadership Team. He serves as associate director of flagship disease projects for the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease at the Broad. Dr. Neale is an associate professor in the Analytic and Translational Genetics Unit (ATGU) at Massachusetts General Hospital (MGH), where he directs the Genomics of Public Health Initiative. He is an associate professor in medicine at Harvard Medical School (HMS).

Dr. Neale’s work centers on large-scale genomic data analysis from global biobanks, developing statistical and AI methods to study diseases, especially mental illnesses. He has led major genetic studies on conditions like ADHD, autism, type 2 diabetes, bipolar disorder and schizophrenia, and directs rare variant research in psychiatric disorders. His lab created Hail, a widely used tool for scalable genetic analysis, and developed key genomic assays used on millions of DNA samples. He also plays a leading role in major international collaborations, including SCHEMA, BipEx, the Global Biobank Meta-analysis Initiative, and the COVID-19 Host Genetics Initiative.

Dr. Neale studied at the University of Chicago and Virginia Commonwealth University, earning a B.Sc. in genetics. He went on to earn his Ph.D. in human genetics from King’s College in London, UK. Dr. Neale completed his postdoctoral training in Mark Daly’s laboratory at Massachusetts General Hospital.

Dr. Walsh is Chief of the Division of Genetics and Genomics at Boston Children’s Hospital, an Investigator of the Howard Hughes Medical Institute (HHMI), and Bullard Professor of Neurology and Pediatrics at Harvard Medical School.

Previously, he served as Assistant Professor of Neurology at Beth Israel-Deaconess Medical Center, later becoming the Bullard Professor.

Dr. Walsh is an elected fellow of the American Association for the Advancement of Sciences, and an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the Norwegian Academy of Science and Letters, and the National Academy of Sciences. He received the UNC-Perl Neuroscience Award in 2018, the Gruber Neuroscience Prize in 2021, and the Kavli Neuroscience Prize in 2022, among other honors. He has served on the National Advisory Mental Health Council of the NIMH, the Multi-Council Working Group on the BRAIN Initiative, the Scientific Advisory Board of the Imagine Institut (Paris), and Advisory Committees to Maze Therapeutics, the Institute for Protein Innovation, the Allen Brain Institute, and the Weizmann Institute, among others.

Dr. Walsh completed his PhD and MD at The University of Chicago, followed by internship, neurology residency and chief residency at Massachusetts General Hospital. He pursued postdoctoral training in Genetics at Harvard Medical School.

Leonard Zon, MD, is the Grousbeck Professor of Pediatric Medicine at Harvard Medical School, an Investigator at the Howard Hughes Medical Institute, and Director of the Stem Cell Program at Boston Children’s Hospital.

Dr. Zon is founder and former president of the International Society for Stem Cell Research and Chair of the Executive Committee of the Harvard Stem Cell Institute. Dr. Zon has received numerous honors, including election to the Institute of Medicine of the National Academies (2005), the American Academy of Arts & Sciences (2008), and the National Academy of Sciences (2022). Additional recognitions include the E. Donnall Thomas Lecture and Prize from the American Society of Hematology (2010), the ISEH Donald Metcalf Lecture Award (2013), the Boston Children’s Hospital Post-Doctoral Association Mentoring Award (2014), and the National Cancer Institute’s Alfred G. Knudson Award (2015).

Dr. Zon received his BS in chemistry and natural sciences from Muhlenberg College and his MD from Jefferson Medical College. He subsequently completed an internal medicine residency at New England Deaconess Hospital, a fellowship in medical oncology at Dana-Farber Cancer Institute, and postdoctoral research in Stuart Orkin’s laboratory.